Physician profile
Ashish Pal
NPI 1376588582
$1,975.80
in general payments reported to CMS, 2019-2025
22 companies · $65.11 in 2025
The $65.11 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $432 · 2020: $381 · 2021: $178 · 2022: $384 · 2023: $342 · 2024: $194 · 2025: $65.11.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $600.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $600.39 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $330.83 | 2020-2024 | Jardiance |
| Merck Sharp & Dohme LLC | $292.58 | 2021-2025 | Verquvo |
| Bard Peripheral Vascular, INC. | $251.23 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $156.29 | 2019-2023 | Xarelto |
| E.R. Squibb & Sons, L.L.C. | $137.04 | 2019-2020 | |
| Biocompatibles, INC. | $112.92 | 2019 | |
| Kiniksa Pharmaceuticals, Ltd. | $103.53 | 2022-2023 | Arcalyst |
| Kiniksa Pharmaceuticals International, Plc | $91.97 | 2024 | Arcalyst |
| Boston Scientific Corporation | $91.93 | 2019-2024 | Varithena Administration Pack |
| Abbott Laboratories | $72.02 | 2019-2020 | |
| Lexicon Pharmaceuticals, INC. | $42.24 | 2023 | Inpefa |
| Cordis US Corp. | $41.24 | 2024 | Saber |
| Pfizer INC. | $40.24 | 2019-2023 | |
| Btg International INC. | $39.48 | 2019 | |
| Angiodynamics, INC. | $37.00 | 2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $31.69 | 2021-2022 | |
| Amgen INC. | $21.38 | 2025 | Repatha |
| Philips North America LLC | $18.64 | 2019 | |
| Becton, Dickinson and Company | $18.61 | 2025 | Venovo |
| Medtronic Vascular, INC. | $15.96 | 2020 | |
| Novartis Pharmaceuticals Corporation | $14.93 | 2021 | |
| Coala Life INC | $14.05 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashish Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.